Nxera Pharma Co (FRA:JSS) E10: €-0.11 (As of Mar. 2026)


FRA:JSS Nxera Pharma Co Ltd FRA:JSS
73 GF Score
Price €5.10
GF Value €6.99
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co E10?

Nxera Pharma Co FRA:JSS -0.97% 73 E10 is €-0.11 as of Mar. 2026. GuruFocus rates FRA:JSS with a GF Score™ of 73/100 and a GF Value™ of €6.99. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nxera Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.046. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.11 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-03), Nxera Pharma Co's current stock price is €5.10. Nxera Pharma Co's E10 for the quarter that ended in Mar. 2026 was €-0.11. Nxera Pharma Co's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Nxera Pharma Co was 600.00. The lowest was 124.27. And the median was 268.05.


Nxera Pharma Co  (FRA:JSS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Nxera Pharma Co was 600.00. The lowest was 124.27. And the median was 268.05.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nxera Pharma Co E10 Related Terms


Nxera Pharma Co E10 Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co E10 Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.08 -0.01 -0.05 -0.14

Nxera Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.06 -0.07 -0.14 -0.11

FRA:JSS vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Shiller PE Ratio falls into.


FRA:JSS
73GF Score
Nxera Pharma Co Ltd FRA:JSS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.046/112.7000*112.7000
=-0.046

Current CPI (Mar. 2026) = 112.7000.

Nxera Pharma Co Quarterly Data

per share eps CPI Adj_EPS
201606 1.389 98.100 1.596
201609 -0.056 98.000 -0.064
201612 0.007 98.400 0.008
201703 -0.110 98.100 -0.126
201706 0.035 98.500 0.040
201709 -0.108 98.800 -0.123
201712 -0.128 99.400 -0.145
201803 -0.097 99.200 -0.110
201806 -0.160 99.200 -0.182
201809 -0.208 99.900 -0.235
201812 -0.272 99.700 -0.307
201903 0.106 99.700 0.120
201906 -0.067 99.800 -0.076
201909 0.116 100.100 0.131
201912 -0.003 100.500 -0.003
202003 -0.081 100.300 -0.091
202006 -0.147 99.900 -0.166
202009 0.047 99.900 0.053
202012 0.314 99.300 0.356
202103 -0.110 99.900 -0.124
202106 -0.106 99.500 -0.120
202109 0.044 100.100 0.050
202112 0.271 100.100 0.305
202203 -0.194 101.100 -0.216
202206 -0.127 101.800 -0.141
202209 0.027 103.100 0.030
202212 0.308 104.100 0.333
202303 -0.120 104.400 -0.130
202306 -0.052 105.200 -0.056
202309 -0.379 106.200 -0.402
202312 -0.014 106.800 -0.015
202403 -0.225 107.200 -0.237
202406 -0.093 108.200 -0.097
202409 0.085 108.900 0.088
202412 -0.092 110.700 -0.094
202503 -0.052 111.100 -0.053
202506 -0.158 111.700 -0.159
202509 -0.107 112.000 -0.108
202512 -0.468 113.000 -0.467
202603 -0.046 112.700 -0.046

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.11 mean?
Nxera Pharma Co (FRA:JSS) has a E10 of €-0.11 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's E10 too high?
Nxera Pharma Co's current E10 is €-0.11. Overall, Nxera Pharma Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's E10 compare to VRTX and REGN?
Nxera Pharma Co's E10 of €-0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current E10 is €-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Nxera Pharma Co (FRA:JSS) has a current E10 of €-0.11. The stock's GF Value™ is €6.99, compared to a current price of €5.10 — trading 27% below its estimated fair value. The current E10 is €-0.11. Nxera Pharma Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nxera Pharma Co (FRA:JSS), the current E10 is €-0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of €5.10 is trading 27% below its estimated GF Value™ of €6.99.

Key valuation signals for FRA:JSS:

  • E10: €-0.11
  • GF Value™: €6.99 vs. price of €5.10 (27% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
73GF Score

Get the complete analysis for FRA:JSS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.10
Price
€6.99
GF Value